Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
Top Cited Papers
- 20 March 2010
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (9), 1450-1457
- https://doi.org/10.1200/jco.2009.23.0839
Abstract
Purpose We investigated the respective contribution (in terms of cancer yield and stage at diagnosis) of clinical breast examination (CBE), mammography, ultrasound, and quality-assured breast magnetic resonance imaging (MRI), used alone or in different combination, for screening women at elevated risk for breast cancer. Methods Prospective multicenter observational cohort study. Six hundred eighty-seven asymptomatic women at elevated familial risk (≥ 20% lifetime) underwent 1,679 annual screening rounds consisting of CBE, mammography, ultrasound, and MRI, read independently and in different combinations. In a subgroup of 371 women, additional half-yearly ultrasound and CBE was performed more than 869 screening rounds. Mean and median follow-up was 29.18 and 29.09 months. Results Twenty-seven women were diagnosed with breast cancer: 11 ductal carcinoma in situ (41%) and 16 invasive cancers (59%). Three (11%) of 27 were node positive. All cancers were detected during annual screening; no interval cancer occurred; no cancer was identified during half-yearly ultrasound. The cancer yield of ultrasound (6.0 of 1,000) and mammography (5.4 of 1,000) was equivalent; it increased nonsignificantly (7.7 of 1,000) if both methods were combined. Cancer yield achieved by MRI alone (14.9 of 1,000) was significantly higher; it was not significantly improved by adding mammography (MRI plus mammography: 16.0 of 1,000) and did not change by adding ultrasound (MRI plus ultrasound: 14.9 of 1,000). Positive predictive value was 39% for mammography, 36% for ultrasound, and 48% for MRI. Conclusion In women at elevated familial risk, quality-assured MRI screening shifts the distribution of screen-detected breast cancers toward the preinvasive stage. In women undergoing quality-assured MRI annually, neither mammography, nor annual or half-yearly ultrasound or CBE will add to the cancer yield achieved by MRI alone.Keywords
This publication has 65 references indexed in Scilit:
- Management of an Inherited Predisposition to Breast CancerThe New England Journal of Medicine, 2007
- American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to MammographyCA: A Cancer Journal for Clinicians, 2007
- Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation StatementAnnals of Internal Medicine, 2005
- Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation CarriersJournal of Clinical Oncology, 2002
- An audit of screening for familial breast cancer before 50 years in the South Thames Region – have we got it right?Familial Cancer, 2002
- The incidence of breast cancer from screening women according to predicted family history riskEuropean Journal of Cancer, 2001
- Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial RiskJournal of Clinical Oncology, 2001
- Screening women with a family history of breast cancer—results from the British Familial Breast Cancer GroupEuropean Journal of Surgical Oncology, 2000
- Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc CommitteeAnnals of Oncology, 1998
- Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to CancerJAMA, 1997